Compare Stocks: BRTX, AKTX, CMMB, and ALVR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$10.84 +6.8%	$9.58	$3.02 ▼ $49.60	$19.76M	1.43	76,098 shs	61,944 shs
ALVR AlloVir	$3.90 -0.5%	$4.15	$7.96 ▼ $24.15	$19.67M	0.63	15,685 shs	17,271 shs
BRTX Biorestorative Therapies	$0.14 -28.8%	$0.27	$0.14 ▼ $1.73	$5.14M	0.83	225,649 shs	3.50 million shs
CMMB Chemomab Therapeutics	$2.83 +3.7%	$1.92	$1.35 ▼ $3.58	$19.78M	0.76	102,270 shs	150,841 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+6.80%	+20.31%	+39.15%	-28.07%	-58.63%
ALVR AlloVir	-0.51%	-4.41%	-3.70%	-16.31%	-2.50%
BRTX Biorestorative Therapies	-28.76%	-30.24%	-31.57%	-64.52%	-91.69%
CMMB Chemomab Therapeutics	+3.66%	+4.04%	+68.45%	+59.89%	-6.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$10.84 +6.8%	$9.58	$3.02 ▼ $49.60	$19.76M	1.43	76,098 shs	61,944 shs
ALVR AlloVir	$3.90 -0.5%	$4.15	$7.96 ▼ $24.15	$19.67M	0.63	15,685 shs	17,271 shs
BRTX Biorestorative Therapies	$0.14 -28.8%	$0.27	$0.14 ▼ $1.73	$5.14M	0.83	225,649 shs	3.50 million shs
CMMB Chemomab Therapeutics	$2.83 +3.7%	$1.92	$1.35 ▼ $3.58	$19.78M	0.76	102,270 shs	150,841 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+6.80%	+20.31%	+39.15%	-28.07%	-58.63%
ALVR AlloVir	-0.51%	-4.41%	-3.70%	-16.31%	-2.50%
BRTX Biorestorative Therapies	-28.76%	-30.24%	-31.57%	-64.52%	-91.69%
CMMB Chemomab Therapeutics	+3.66%	+4.04%	+68.45%	+59.89%	-6.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.50	Moderate Buy	$32.33	198.28% Upside
ALVR AlloVir	0.00	N/A	N/A	N/A
BRTX Biorestorative Therapies	1.00	Sell	N/A	N/A
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRTX, AKTX, CMMB, and ALVR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	BRTX Biorestorative Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$9.55 per share	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
BRTX Biorestorative Therapies	$360K	10.17	N/A	N/A	$0.04 per share	3.59
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$1.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	N/A
ALVR AlloVir	-$190.42M	-$20.23	N/A	N/A	N/A	N/A	-71.03%	-61.27%	N/A
BRTX Biorestorative Therapies	-$14.24M	-$1.07	N/A	N/A	N/A	-3,088.27%	-508.42%	-230.94%	9/8/2026 (Estimated)
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)

Latest BRTX, AKTX, CMMB, and ALVR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/8/2026	Q2 2026	BRTX Biorestorative Therapies	-$0.10	N/A	N/A	N/A	$0.60 million	N/A
8/19/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
ALVR AlloVir	N/A	86.78	86.78
BRTX Biorestorative Therapies	N/A	2.35	2.35
CMMB Chemomab Therapeutics	N/A	6.41	6.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
ALVR AlloVir	66.05%
BRTX Biorestorative Therapies	69.38%
CMMB Chemomab Therapeutics	46.05%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
ALVR AlloVir	32.07%
BRTX Biorestorative Therapies	13.60%
CMMB Chemomab Therapeutics	11.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	1.95 million	1.32 million	Not Optionable
ALVR AlloVir	110	5.04 million	3.43 million	No Data
BRTX Biorestorative Therapies	7	25.48 million	22.01 million	Not Optionable
CMMB Chemomab Therapeutics	20	7.25 million	6.38 million	Not Optionable

BRTX, AKTX, CMMB, and ALVR Headlines

Recent News About These Companies

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

August 31, 2026 | globenewswire.com

Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 19, 2026 | finanznachrichten.de

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 19, 2026 | globenewswire.com

Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

July 8, 2026 | seekingalpha.com

Chemomab to merge with Scipher Medicine

July 8, 2026 | msn.com

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

July 8, 2026 | globenewswire.com

Chemomab Therapeutics Stock Short Interest Report | NASDAQ:CMMB | Benzinga

July 7, 2026 | benzinga.com

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026 | globenewswire.com

Chemomab Therapeutics Ltd ADR CMMB

May 8, 2026 | morningstar.comM

Chemomab Therapeutics - Depositary Receipt (CMMB) price target decreased by 14.29% to 15.30

March 28, 2026 | msn.com

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

March 19, 2026 | globenewswire.com

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026 | globenewswire.com

Chemomab Therapeutics - depositary receipt (CMMB) price target decreased by 33.96% to 17.85

February 4, 2026 | msn.com

Maxim Group Keeps Their Buy Rating on Chemomab Therapeutics (CMMB)

December 25, 2025 | theglobeandmail.com

Chemomab Therapeutics announces results of its Phase 2 SPRING trial

December 2, 2025 | msn.com

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

December 2, 2025 | globenewswire.com

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

November 24, 2025 | globenewswire.com

Chemomab Therapeutics Advances PSC Treatment with Phase 3 Trial

November 22, 2025 | msn.com

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 20, 2025 | globenewswire.com

Chemomab announces presentations at AASLD 2025 on nebokitug data

November 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, AKTX, CMMB, and ALVR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$10.84 +0.69 (+6.80%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$10.86 +0.03 (+0.23%)

As of 04:06 AM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AlloVir NASDAQ:ALVR

$3.90 -0.02 (-0.51%)

As of 09/2/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Biorestorative Therapies NASDAQ:BRTX

$0.14 -0.06 (-28.76%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.14 +0.00 (+0.90%)

As of 06:53 AM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Chemomab Therapeutics NASDAQ:CMMB

$2.83 +0.10 (+3.66%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$2.84 +0.00 (+0.18%)

As of 06:53 AM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRTX, AKTX, CMMB, and ALVR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRTX, AKTX, CMMB, and ALVR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRTX, AKTX, CMMB, and ALVR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, AKTX, CMMB, and ALVR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

AlloVir NASDAQ:ALVR

Biorestorative Therapies NASDAQ:BRTX

Chemomab Therapeutics NASDAQ:CMMB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRTX, AKTX, CMMB, and ALVR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRTX, AKTX, CMMB, and ALVR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRTX, AKTX, CMMB, and ALVR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, AKTX, CMMB, and ALVR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

AlloVir NASDAQ:ALVR

Biorestorative Therapies NASDAQ:BRTX

Chemomab Therapeutics NASDAQ:CMMB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools